Methotrexate 500 Mg/20 Ml Fresenius, Methotrexate 50 Mg/2 Ml Fresenius 500 mg/20 mL, 50 mg/2 mL Injection
PDF Leaflet Revision Date: 04 August 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers, severe psoriasis, and rheumatoid arthritis.
Dosage (summary)
Varies by condition; e.g., 30 mg/m2 twice weekly for maintenance in leukemia.
Onset of Action / Duration
Onset: 4-6 weeks for leukemia remission.
Special Populations
- Elderly
- Pediatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; causes embryotoxicity.
Key Drug Interactions
- NSAIDs
- Penicillins
- Proton pump inhibitors
Contraindications
- Hypersensitivity to methotrexate
- Pregnancy
- Severe renal/liver disorders
Common side effects
- Nausea
- Leukopenia
- Stomatitis
- Fatigue
Counselling Points
- Avoid pregnancy during treatment
- Report any signs of infection
- Regular blood tests required
Serious warnings
- Serious toxicity risk
- Monitor for bone marrow and liver toxicity
Important Disclaimer
The Methotrexate 500 Mg/20 Ml Fresenius, Methotrexate 50 Mg/2 Ml Fresenius 500 mg/20 mL, 50 mg/2 mL Injection professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
